![Xin Nakanishi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Xin Nakanishi
Director/Miembro de la Junta en ONCTERNAL THERAPEUTICS, INC. .
Fortuna: - $ al 31/05/2024
Cargos activos de Xin Nakanishi
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ONCTERNAL THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/11/2018 | - |
Independent Dir/Board Member | 01/11/2018 | - | |
Shanghai Pharma Biotherapeutics Usa, Inc. | Director Ejecutivo | 01/07/2018 | - |
Historial de carrera de Xin Nakanishi
Antiguos cargos conocidos de Xin Nakanishi.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Sunvita Therapeutics, LLC | Director Ejecutivo | 01/01/2009 | 01/01/2018 |
Fundador | 01/01/2009 | 01/01/2018 | |
Yuansheng Bioventure, Inc. | Corporate Officer/Principal | 01/01/2017 | 01/01/2018 |
Phenomix Corp.
![]() Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Corporate Officer/Principal | - | - |
Oncternal Oncology, Inc.
![]() Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Director/Miembro de la Junta | - | - |
Formación de Xin Nakanishi.
Wuhan University | Undergraduate Degree |
University of Kansas | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
China | 3 |
Operativa
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Corporate Officer/Principal | 2 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ONCTERNAL THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Oncternal Oncology, Inc.
![]() Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Health Technology |
Shanghai Pharma Biotherapeutics Usa, Inc. | |
Yuansheng Bioventure, Inc. | |
Sunvita Therapeutics, LLC | |
Phenomix Corp.
![]() Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
- Bolsa de valores
- Insiders
- Xin Nakanishi
- Experiencia